Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab in HER2-negative breast cancer
NCT04498793Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in breast cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Status: unknown.
02
Drugs
tislelizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04498793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498793.